

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
S30	6	(S23 OR S24 OR S25 OR S26 OR S27 OR S28) AND conjugate.ab. AND toxin.ab.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2005/02/16 15:07
S29	1077	(S23 OR S24 OR S25 OR S26 OR S27 OR S28) AND conjugate AND toxin	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2005/02/16 15:07
S28	811	530/345.ccls.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2005/02/16 15:07
S27	2286	530/328.ccls.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2005/02/16 15:06
S26	3882	530/324.ccls.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2005/02/16 15:06
S25	300	530/313.ccls.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2005/02/16 15:06
S24	1160	514/14.ccls.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2005/02/16 15:06
S23	8038	514/12.ccls.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2005/02/16 15:06
S22	86	(GnRH OR LHRH) SAME toxin	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2005/02/10 14:51
S21	21	(514/12.ccls. OR 514/14.ccls. OR 530/313.ccls. OR 530/324.ccls. OR 530/328.ccls. OR 530/345.ccls.) AND ((GnRH OR LHRH) SAME toxin)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2005/02/10 14:42
S20	1	((GnRH OR LHRH) ADJ conjugate) SAME toxin	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2005/02/10 14:42
S19	11	Nett-Torr\$.in.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2005/02/10 14:40

S4	27	methotrexate.clm. AND doxorubicin.clm. AND daunomycin.clm.	USPAT	OR	OFF	2004/08/19 13:32
S3	6	methotrexate.clm. AND (nitrogen ADJ mustard).clm. AND doxorubicin.clm. AND daunomycin.clm.	USPAT	OR	OFF	2004/08/19 13:32
S1	80	methotrexate SAME (nitrogen ADJ mustard) SAME doxorubicin SAME daunomycin	USPAT	OR	OFF	2004/08/19 13:14
S2	5	methotrexate SAME (nitrogen ADJ mustard) SAME doxorubicin SAME daunomycin.clm.	USPAT	OR	OFF	2004/08/19 13:12
S15	18	(514/12.ccls. OR 514/14.ccls. OR 530/313.ccls. OR 530/324.ccls. OR 530/328.ccls. OR 530/345.ccls.) AND ((GnRH OR LHRH) SAME toxin)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2004/08/19 10:08
S14	71	(GnRH OR LHRH) SAME toxin	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2004/08/19 10:08
S13	794	530/345.ccls.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2004/08/19 10:07
S12	2200	530/328.ccls.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2004/08/19 10:07
S11	3717	530/324.ccls.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2004/08/19 10:07
S10	296	530/313.ccls.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2004/08/19 10:07
S9	1081	514/14.ccls.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2004/08/19 10:07
S8	7248	514/12.ccls.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2004/08/19 10:07
S7	2	(carlson.xa. OR carlson.xp.) AND LHRH.clm.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2004/08/19 10:07

S6	11	Nett-Torr\$.in.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2004/08/05 10:57
S5	1	((GnRH OR LHRH) ADJ conjugate) SAME toxin	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2004/08/05 10:40

## Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: ssspta1653aud

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 SEP 01 New pricing for the Save Answers for SciFinder Wizard within STN Express with Discover!  
NEWS 4 OCT 28 KOREAPAT now available on STN  
NEWS 5 NOV 30 PHAR reloaded with additional data  
NEWS 6 DEC 01 LISA now available on STN  
NEWS 7 DEC 09 12 databases to be removed from STN on December 31, 2004  
NEWS 8 DEC 15 MEDLINE update schedule for December 2004  
NEWS 9 DEC 17 ELCOM reloaded; updating to resume; current-awareness alerts (SDIs) affected  
NEWS 10 DEC 17 COMPUAB reloaded; updating to resume; current-awareness alerts (SDIs) affected  
NEWS 11 DEC 17 SOLIDSTATE reloaded; updating to resume; current-awareness alerts (SDIs) affected  
NEWS 12 DEC 17 CERAB reloaded; updating to resume; current-awareness alerts (SDIs) affected  
NEWS 13 DEC 17 THREE NEW FIELDS ADDED TO IFIPAT/IFIUDB/IFICDB  
NEWS 14 DEC 30 EPFULL: New patent full text database to be available on STN  
NEWS 15 DEC 30 CAPLUS - PATENT COVERAGE EXPANDED  
NEWS 16 JAN 03 No connect-hour charges in EPFULL during January and February 2005  
NEWS 17 JAN 26 CA/CAPLUS - Expanded patent coverage to include the Russian Agency for Patents and Trademarks (ROSPATENT)  
NEWS 18 FEB 10 STN Patent Forums to be held in March 2005  
NEWS 19 FEB 16 STN User Update to be held in conjunction with the 229th ACS National Meeting on March 13, 2005  
  
NEWS EXPRESS JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005  
  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 15:10:16 ON 16 FEB 2005

=> index bioscience

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED  
COST IN U.S. DOLLARS

**FULL ESTIMATED COST**      **ENTRY**      **SESSION**  
0.21      0.21

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS. . . .' ENTERED AT 15:10:41 ON 16 FEB 2005

75 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view search error messages that display as 0\* with SET DETAIL OFF.

=> s gonadotroph AND conjugate

1 FILE BIOBUSINESS  
4 FILE BIOENG  
7 FILE BIOSIS  
1 FILE BIOTECHABS  
1 FILE BIOTECHDS  
1 FILE BIOTECHNO  
1 FILE CANCERLIT  
22 FILE CAPLUS  
21 FILE DGENE  
1 FILE DRUGU  
4 FILE EMBASE  
3 FILE ESBIOBASE  
2 FILE FEDRIP

37 FILES SEARCHED...

```
9  FILE IFIPAT
5  FILE LIFESCI
6  FILE MEDLINE
2  FILE PASCAL
3  FILE SCISEARCH
16 FILE TOXCENTER
43 FILE USPATFULL
5  FILE USPAT2
1  FILE VETU
8  FILE WPIDS
8  FILE WPINDEX
```

24 FILES HAVE ONE OR MORE ANSWERS.

75 FILES SEARCHED IN STNINDEX

## 1.1 QUE GONADOTROPH AND CONJUGATE

=> d rank

F1	43	USPATFULL
F2	22	CAPLUS
F3	21	DGENE
F4	16	TOXCENTER
F5	9	IFIPAT
F6	8	WPIDS
F7	8	WPINDEX
F8	7	BIOSIS
F9	6	MEDLINE
F10	5	LIFESCI
F11	5	USPAT2

F12	4	BIOENG
F13	4	EMBASE
F14	3	ESBIOBASE
F15	3	SCISEARCH
F16	2	FEDRIP
F17	2	PASCAL
F18	1	BIOBUSINESS
F19	1	BIOTECHABS
F20	1	BIOTECHDS
F21	1	BIOTECHNO
F22	1	CANCERLIT
F23	1	DRUGU
F24	1	VETU

=> file f9, f1, f2, f3, f4, f5, f6, f7, f8, f13		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	1.77	1.98

FILE 'MEDLINE' ENTERED AT 15:12:23 ON 16 FEB 2005

FILE 'USPATFULL' ENTERED AT 15:12:23 ON 16 FEB 2005  
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CAPLUS' ENTERED AT 15:12:23 ON 16 FEB 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 15:12:23 ON 16 FEB 2005  
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'TOXCENTER' ENTERED AT 15:12:23 ON 16 FEB 2005  
COPYRIGHT (C) 2005 ACS

FILE 'IFIPAT' ENTERED AT 15:12:23 ON 16 FEB 2005  
COPYRIGHT (C) 2005 IFI CLAIMS(R) Patent Services (IFI)

FILE 'WPIDS' ENTERED AT 15:12:23 ON 16 FEB 2005  
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

FILE 'BIOSIS' ENTERED AT 15:12:23 ON 16 FEB 2005  
Copyright (c) 2005 The Thomson Corporation.

FILE 'EMBASE' ENTERED AT 15:12:23 ON 16 FEB 2005  
COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

=> s gonadotroph AND toxin  
L2 244 GONADOTROPH AND TOXIN

=> s conjugate AND gonadotroph  
5 FILES SEARCHED...  
L3 136 CONJUGATE AND GONADOTROPH

=> s L3 AND toxin  
L4 79 L3 AND TOXIN

=> dup rem 14  
DUPLICATE IS NOT AVAILABLE IN 'DGENE'.  
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE

PROCESSING COMPLETED FOR L4  
L5 47 DUP REM L4 (32 DUPLICATES REMOVED)

=> s L5 and sterilize  
L6 14 L5 AND STERILIZE

=> s nett,t?/au  
L7 834 NETT,T?/AU

=> dup rem 17  
DUPLICATE IS NOT AVAILABLE IN 'DGENE'.  
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE  
PROCESSING COMPLETED FOR L7  
L8 333 DUP REM L7 (501 DUPLICATES REMOVED)

=> d his

(FILE 'HOME' ENTERED AT 15:10:16 ON 16 FEB 2005)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,  
AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS,  
BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB,  
CROPU, DDFB, DDFU, DGENE, DISSABS, ...' ENTERED AT 15:10:41 ON 16 FEB 2005  
SEA GONADOTROPH AND CONJUGATE

-----  
1 FILE BIOBUSINESS  
4 FILE BIOENG  
7 FILE BIOSIS  
1 FILE BIOTECHABS  
1 FILE BIOTECHDS  
1 FILE BIOTECHNO  
1 FILE CANCERLIT  
22 FILE CAPLUS  
21 FILE DGENE  
1 FILE DRUGU  
4 FILE EMBASE  
3 FILE ESBIOBASE  
2 FILE FEDRIP  
9 FILE IFIPAT  
5 FILE LIFESCI  
6 FILE MEDLINE  
2 FILE PASCAL  
3 FILE SCISEARCH  
16 FILE TOXCENTER  
43 FILE USPATFULL  
5 FILE USPAT2  
1 FILE VETU  
8 FILE WPIDS  
8 FILE WPINDEX

L1 QUE GONADOTROPH AND CONJUGATE

-----  
FILE 'MEDLINE, USPATFULL, CAPLUS, DGENE, TOXCENTER, IFIPAT, WPIDS,  
BIOSIS, EMBASE' ENTERED AT 15:12:23 ON 16 FEB 2005

L2 244 S GONADOTROPH AND TOXIN  
L3 136 S CONJUGATE AND GONADOTROPH  
L4 79 S L3 AND TOXIN  
L5 47 DUP REM L4 (32 DUPLICATES REMOVED)  
L6 14 S L5 AND STERILIZE  
L7 834 S NETT,T?/AU  
L8 333 DUP REM L7 (501 DUPLICATES REMOVED)

=> s L6 NOT L8

L9

2 L6 NOT L8

=> d his

(FILE 'HOME' ENTERED AT 15:10:16 ON 16 FEB 2005)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, ...' ENTERED AT 15:10:41 ON 16 FEB 2005  
SEA GONADOTROPH AND CONJUGATE

-----  
1 FILE BIOBUSINESS  
4 FILE BIOENG  
7 FILE BIOSIS  
1 FILE BIOTECHABS  
1 FILE BIOTECHDS  
1 FILE BIOTECHNO  
1 FILE CANCERLIT  
22 FILE CAPLUS  
21 FILE DGENE  
1 FILE DRUGU  
4 FILE EMBASE  
3 FILE ESBIOBASE  
2 FILE FEDRIP  
9 FILE IFIPAT  
5 FILE LIFESCI  
6 FILE MEDLINE  
2 FILE PASCAL  
3 FILE SCISEARCH  
16 FILE TOXCENTER  
43 FILE USPATFULL  
5 FILE USPAT2  
1 FILE VETU  
8 FILE WPIDS  
8 FILE WPINDEX

L1

QUE GONADOTROPH AND CONJUGATE

-----

FILE 'MEDLINE, USPATFULL, CAPLUS, DGENE, TOXCENTER, IFIPAT, WPIDS, BIOSIS, EMBASE' ENTERED AT 15:12:23 ON 16 FEB 2005

L2 244 S GONADOTROPH AND TOXIN  
L3 136 S CONJUGATE AND GONADOTROPH  
L4 79 S L3 AND TOXIN  
L5 47 DUP REM L4 (32 DUPLICATES REMOVED)  
L6 14 S L5 AND STERILIZE  
L7 834 S NETT, T?/AU  
L8 333 DUP REM L7 (501 DUPLICATES REMOVED)  
L9 2 S L6 NOT L8

=> d 19 ibib ti abs 1-2

L9 ANSWER 1 OF 2 USPATFULL on STN

ACCESSION NUMBER: 2004:25125 USPATFULL

TITLE: Ligand/lytic peptide compositions and methods of use

INVENTOR(S): Enright, Frederick M., Baton Rouge, LA, UNITED STATES

Jaynes, Jesse M., Raleigh, NC, UNITED STATES

Hansel, William, Baton Rouge, LA, UNITED STATES

Koonce, Kenneth L., Baton Rouge, LA, UNITED STATES

McCann, Samuel M., Baton Rouge, LA, UNITED STATES

Yu, Wen H., Baton Rouge, LA, UNITED STATES

Melrose, Patricia A., Baton Rouge, LA, UNITED STATES

Foil, Lane D., Baton Rouge, LA, UNITED STATES

Elzer, Philip H., Baton Rouge, LA, UNITED STATES

NUMBER      KIND      DATE

PATENT INFORMATION:      US 2004018967      A1      20040129  
APPLICATION INFO.:      US 2003-617561      A1      20030711 (10)  
RELATED APPLN. INFO.:      Continuation of Ser. No. US 1999-381879, filed on 24  
Sep 1999, GRANTED, Pat. No. US 6635740 A 371 of  
International Ser. No. WO 1998-US6114, filed on 27 Mar  
1998, PENDING

NUMBER      DATE

PRIORITY INFORMATION:      US 1997-41009P      19970327 (60)  
US 1997-92112P      19970604 (60)  
US 1997-57456P      19970903 (60)

DOCUMENT TYPE:      Utility

FILE SEGMENT:      APPLICATION

LEGAL REPRESENTATIVE:      PATENT DEPARTMENT, TAYLOR, PORTER, BROOKS & PHILLIPS,  
L.L.P., P.O. BOX 2471, BATON ROUGE, LA, 70821-2471

NUMBER OF CLAIMS:      128

EXEMPLARY CLAIM:      1

LINE COUNT:      2095

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI      Ligand/lytic peptide compositions and methods of use

AB      Amphipathic lytic peptides are ideally suited to use in a ligand/cytotoxin combination to specifically inhibit cells that are driven by or are dependent upon a specific ligand interaction; for example, to induce sterility or long-term contraception, or to attack tumor cells, or to selectively lyse virally-infected cells, or to attack lymphocytes responsible for autoimmune diseases. The peptides act directly on cell membranes, and need not be internalized. Administering a combination of gonadotropin-releasing hormone (GnRH) (or a GnRH agonist) and a membrane-active lytic peptide produces long-term contraception or sterilization in animals in vivo. Administering in vivo a combination of a ligand and a membrane-active lytic peptide kills cells with a receptor for the ligand. The compounds are relatively small, and are not antigenic. Lysis of gonadotropes has been observed to be very rapid (on the order of ten minutes.) Lysis of tumor cells is rapid. The two components--the ligand and the lytic peptide--may optionally be administered as a fusion peptide, or they may be administered separately, with the ligand administered slightly before the lytic peptide, to activate cells with receptors for the ligand, and thereby make those cells susceptible to lysis by the lytic peptide. The compounds may be used in gene therapy to treat malignant or non-malignant tumors, and other diseases caused by clones or populations of "normal" host cells bearing specific receptors (such as lymphocytes), because genes encoding a lytic peptide or encoding a lytic peptide/peptide hormone fusion may readily be inserted into hematopoietic stem cells or myeloid precursor cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9      ANSWER 2 OF 2      USPATFULL on STN

ACCESSION NUMBER:      2003:279230      USPATFULL

TITLE:      Ligand/lytic peptide compositions and methods of use

INVENTOR(S):      Enright, Frederick M., Baton Rouge, LA, United States

Jaynes, Jesse M., Baton Rouge, LA, United States

Hansel, William, Baton Rouge, LA, United States

Koonce, Kenneth L., Baton Rouge, LA, United States

McCann, Samuel M., Baton Rouge, LA, United States

Yu, Wen H., Baton Rouge, LA, United States

Melrose, Patricia A., Baton Rouge, LA, United States

PATENT ASSIGNEE(S):  
Foil, Lane D., Baton Rouge, LA, United States  
Elzer, Philip H., Baton Rouge, LA, United States  
Board of Supervisors of Louisiana State University and  
Agricultural and Mechanical College, Baton Rouge, LA,  
United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6635740	B1	20031021
	WO 9842365		19981001
APPLICATION INFO.:	US 1999-381879		19990924 (9)
	WO 1998-US6114		19980327

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-57456P	19970903 (60)
	US 1997-92112P	19970604 (60)
	US 1997-41009P	19970327 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: GRANTED  
PRIMARY EXAMINER: Low, Christopher S. F.  
ASSISTANT EXAMINER: Lukton, David  
LEGAL REPRESENTATIVE: Runnels, John H.  
NUMBER OF CLAIMS: 109  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)  
LINE COUNT: 2428  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI Ligand/lytic peptide compositions and methods of use  
AB Amphipathic lytic peptides are ideally suited to use in a ligand/cytotoxin combination to specifically inhibit cells that are driven by or are dependent upon a specific ligand interaction; for example, to induce sterility or long-term contraception, or to attack tumor cells, or to selectively lyse virally-infected cells, or to attack lymphocytes responsible for autoimmune diseases. The peptides act directly on cell membranes, and need not be internalized. Administering a combination of gonadotropin-releasing hormone (GnRH) (or a GnRH agonist) and a membrane-active lytic peptide produces long-term contraception or sterilization in animals *in vivo*. Administering *in vivo* a combination of a ligand and a membrane-active lytic peptide kills cells with a receptor for the ligand. The compounds are relatively small, and are not antigenic. Lysis of gonadotropes has been observed to be very rapid (on the order of ten minutes.) Lysis of tumor cells is rapid. The two components--the ligand and the lytic peptide--may optionally be administered as a fusion peptide, or they may be administered separately, with the ligand administered slightly before the lytic peptide, to activate cells with receptors for the ligand, and thereby make those cells susceptible to lysis by the lytic peptide. The compounds may be used in gene therapy to treat malignant or non-malignant tumors, and other diseases caused by clones or populations of "normal" host cells bearing specific receptors (such as lymphocytes), because genes encoding a lytic peptide or encoding a lytic peptide/peptide hormone fusion may readily be inserted into hematopoietic stem cells or myeloid precursor cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 15:10:16 ON 16 FEB 2005)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,

AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS,  
BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB,  
CROPU, DDFB, DDFU, DGENE, DISSABS, ...' ENTERED AT 15:10:41 ON 16 FEB 2005  
SEA GONADOTROPH AND CONJUGATE

-----  
1 FILE BIOBUSINESS  
4 FILE BIOENG  
7 FILE BIOSIS  
1 FILE BIOTECHABS  
1 FILE BIOTECHDS  
1 FILE BIOTECHNO  
1 FILE CANCERLIT  
22 FILE CAPLUS  
21 FILE DGENE  
1 FILE DRUGU  
4 FILE EMBASE  
3 FILE ESBIOBASE  
2 FILE FEDRIP  
9 FILE IFIPAT  
5 FILE LIFESCI  
6 FILE MEDLINE  
2 FILE PASCAL  
3 FILE SCISEARCH  
16 FILE TOXCENTER  
43 FILE USPATFULL  
5 FILE USPAT2  
1 FILE VETU  
8 FILE WPIDS  
8 FILE WPINDEX

L1 QUE GONADOTROPH AND CONJUGATE

-----  
FILE 'MEDLINE, USPATFULL, CAPLUS, DGENE, TOXCENTER, IFIPAT, WPIDS,  
BIOSIS, EMBASE' ENTERED AT 15:12:23 ON 16 FEB 2005

L2 244 S GONADOTROPH AND TOXIN  
L3 136 S CONJUGATE AND GONADOTROPH  
L4 79 S L3 AND TOXIN  
L5 47 DUP REM L4 (32 DUPLICATES REMOVED)  
L6 14 S L5 AND STERILIZE  
L7 834 S NETT,T?/AU  
L8 333 DUP REM L7 (501 DUPLICATES REMOVED)  
L9 2 S L6 NOT L8

=> s L6 NOT L9  
L10 12 L6 NOT L9

=> d his

(FILE 'HOME' ENTERED AT 15:10:16 ON 16 FEB 2005)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,  
AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS,  
BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB,  
CROPU, DDFB, DDFU, DGENE, DISSABS, ...' ENTERED AT 15:10:41 ON 16 FEB 2005  
SEA GONADOTROPH AND CONJUGATE

-----  
1 FILE BIOBUSINESS  
4 FILE BIOENG  
7 FILE BIOSIS  
1 FILE BIOTECHABS  
1 FILE BIOTECHDS  
1 FILE BIOTECHNO  
1 FILE CANCERLIT

22 FILE CAPLUS  
21 FILE DGENE  
1 FILE DRUGU  
4 FILE EMBASE  
3 FILE ESBIOBASE  
2 FILE FEDRIP  
9 FILE IFIPAT  
5 FILE LIFESCI  
6 FILE MEDLINE  
2 FILE PASCAL  
3 FILE SCISEARCH  
16 FILE TOXCENTER  
43 FILE USPATFULL  
5 FILE USPAT2  
1 FILE VETU  
8 FILE WPIDS  
8 FILE WPINDEX  
L1 QUE GONADOTROPH AND CONJUGATE

---

FILE 'MEDLINE, USPATFULL, CAPLUS, DGENE, TOXCENTER, IFIPAT, WPIDS, BIOSIS, EMBASE' ENTERED AT 15:12:23 ON 16 FEB 2005

L2 244 S GONADOTROPH AND TOXIN  
L3 136 S CONJUGATE AND GONADOTROPH  
L4 79 S L3 AND TOXIN  
L5 47 DUP REM L4 (32 DUPLICATES REMOVED)  
L6 14 S L5 AND STERILIZE  
L7 834 S NETT,T?/AU  
L8 333 DUP REM L7 (501 DUPLICATES REMOVED)  
L9 2 S L6 NOT L8  
L10 12 S L6 NOT L9

=> d 110 ibib ti abs 1-12

L10 ANSWER 1 OF 12 USPATFULL on STN  
ACCESSION NUMBER: 2002:295081 USPATFULL  
TITLE: Method for inactivating **gonadotrophs**  
INVENTOR(S): Nett, Torrance M., Bellvue, CO, UNITED STATES  
Glode, Leonard Michael, Golden, CO, UNITED STATES  
Wieczorek, Maciej, Superior, CO, UNITED STATES  
Jarosz, Paul J., Westminster, CO, UNITED STATES  
PATENT ASSIGNEE(S): Colorado State University Research Foundation (U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002165126	A1	20021107
APPLICATION INFO.:	US 2002-54552	A1	20020121 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-551933, filed on 19 Apr 2000, GRANTED, Pat. No. US 6326467 Continuation of Ser. No. US 1999-354295, filed on 15 Jul 1999, GRANTED, Pat. No. US 6419655 Continuation of Ser. No. US 1998-15729, filed on 7 Apr 1998, GRANTED, Pat. No. US 6103881 Continuation of Ser. No. US 1995-481128, filed on 7 Jun 1995, GRANTED, Pat. No. US 5786457 Continuation of Ser. No. US 1993-94625, filed on 20 Jul 1993, GRANTED, Pat. No. US 5488036 Continuation of Ser. No. US 1993-94250, filed on 20 Jul 1993, GRANTED, Pat. No. US 5492893 Continuation of Ser. No. US 1996-591917, filed on 26 Jan 1996, GRANTED, Pat. No. US 5707964 Continuation of Ser. No. US 1993-88434, filed on 7 Jul 1993, GRANTED, Pat. No. US 5631229 Continuation of Ser. No. US 1992-837639, filed on 14 Feb 1992, GRANTED, Pat.		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-93087P	19980716 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SHERIDAN ROSS PC, 1560 BROADWAY, SUITE 1200, DENVER, CO, 80202	
NUMBER OF CLAIMS:	8	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8	Drawing Page(s)
LINE COUNT:	1392	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI Method for inactivating **gonadotrophs**  
AB Certain toxic compounds (T) such as, for example, compounds based upon diphtheria **toxin**, ricin **toxin**, pseudomonas exotoxin,  $\alpha$ -amanitin, pokeweed antiviral protein (PAP), ribosome inhibiting proteins, especially the ribosome inhibiting proteins of barley, wheat, corn, rye, gelonin and abrin, as well as certain cytotoxic chemicals such as, for example, melphalan and daunomycin can be conjugated to certain analogs of gonadotropin-releasing hormone to form a class of compounds which, when injected into an animal, destroy the **gonadotrophs** of the animal's anterior pituitary gland. Hence such compounds may be used to **sterilize** such animals and/or to treat certain sex hormone related diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 2 OF 12 USPATFULL on STN  
ACCESSION NUMBER: 2002:174569 USPATFULL  
TITLE: Method for controlling animal populations utilizing a sterilant projectile  
INVENTOR(S): Nett, Torrance M., Ft. Collins, CO, United States  
Glode, Leonard Michael, Golden, CO, United States  
PATENT ASSIGNEE(S): Gonex, Inc., Boulder, CO, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6419655	B1	20020716
APPLICATION INFO.:	US 1999-354295		19990715 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-93087P	19980716 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Kennedy, Sharon	
LEGAL REPRESENTATIVE:	Sheridan Ross P.C.	
NUMBER OF CLAIMS:	6	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4	Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT:	621	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI Method for controlling animal populations utilizing a sterilant projectile  
AB A method and device for regulating the population of animals is directed to the use of a sterilant projectile which permanently or temporarily **sterilizes** an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 3 OF 12 USPATFULL on STN  
 ACCESSION NUMBER: 2001:221139 USPATFULL  
 TITLE: Hormone-recombinant **toxin** compounds and methods for using same  
 INVENTOR(S): Nett, Torrance M., Bellvue, CO, United States  
 Glode, Leonard Michael, Golden, CO, United States  
 Wieczorek, Maciej, Superior, CO, United States  
 Jarosz, Paul J., Westminster, CO, United States  
 PATENT ASSIGNEE(S): Colorado State University Research Foundation, Fort Collins, CO, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6326467	B1	20011204
APPLICATION INFO.:	US 2000-551933		20000419 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1998-15729, filed on 7 Apr 1998, now patented, Pat. No. US 6103881 Continuation-in-part of Ser. No. US 1992-837639, filed on 14 Feb 1992, now patented, Pat. No. US 5378688, issued on 3 Jan 1995 Continuation-in-part of Ser. No. US 1989-314653, filed on 23 Feb 1989, now abandoned, said Ser. No. US 837639 And Ser. No. US 551933 Continuation-in-part of Ser. No. US 1993-94625, filed on 20 Jul 1993 Continuation-in-part of Ser. No. US 1993-94250, filed on 20 Jul 1993 Continuation-in-part of Ser. No. US 1993-88434, filed on 7 Jul 1993		

DOCUMENT TYPE: Utility  
FILE SEGMENT: GRANTED  
PRIMARY EXAMINER: Davenport, Avis M.  
LEGAL REPRESENTATIVE: Sheridan Ross P.C.  
NUMBER OF CLAIMS: 3  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 8 Drawing Page(s)  
LINE COUNT: 1409  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI Hormone-recombinant **toxin** compounds and methods for using same  
AB Certain toxic compounds (T) such as, for example, compounds based upon diphtheria **toxin**, ricin **toxin**, pseudomonas exotoxin,  $\alpha$ -amanitin, pokeweed antiviral protein (PAP), ribosome inhibiting proteins, especially the ribosome inhibiting proteins of barley, wheat, corn, rye, gelonin and abrin, as well as certain cytotoxic chemicals such as, for example, melphalan and daunomycin can be conjugated to certain analogs of gonadotropin-releasing hormone to form a class of compounds which, when injected into an animal, destroy the **gonadotrophs** of the animal's anterior pituitary gland. Hence such compounds may be used to **sterilize** such animals and/or to treat certain sex hormone related diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 4 OF 12 USPATFULL on STN  
 ACCESSION NUMBER: 2000:106064 USPATFULL  
 TITLE: GnRH analogs for destroying **gonadotrophs**  
 INVENTOR(S): Nett, Torrance M., Ft. Collins, CO, United States  
 Glode, Leonard Michael, Aurora, CO, United States  
 Karpeisky, Marat, Boulder, CO, United States  
 PATENT ASSIGNEE(S): Colorado State University Research Foundation, Ft. Collins, CO, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6103881		20000815

APPLICATION INFO.: US 1998-15729 19980407 (9)  
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1989-314653, filed  
on 23 Feb 1989, now abandoned 76 Ser. No. US  
1995-481128, filed on 7 Jun 1995, now patented, Pat.  
No. US 5786457

DOCUMENT TYPE: Utility  
FILE SEGMENT: Granted  
PRIMARY EXAMINER: Davenport, Avis M.  
LEGAL REPRESENTATIVE: Sheridan Ross P.C.  
NUMBER OF CLAIMS: 5  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 8 Drawing Page(s)  
LINE COUNT: 1399

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI GnRH analogs for destroying **gonadotrophs**  
AB Certain toxic compounds (T) such as, for example, compounds based upon diphtheria **toxin**, ricin **toxin**, pseudomonas exotoxin,  $\alpha$ -amanitin, pokeweed antiviral protein (PAP), ribosome inhibiting proteins, especially the ribosome inhibiting proteins of barley, wheat, corn, rye, gelonin and abrin, as well as certain cytotoxic chemicals such as, for example, melphalan and daunomycin can be conjugated to certain analogs of gonadotropin-releasing hormone to form a class of compounds which, when injected into an animal, destroy the **gonadotrophs** of the animal's anterior pituitary gland. Hence such compounds may be used to **sterilize** such animals and/or to treat certain sex hormone related diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 5 OF 12 USPATFULL on STN  
ACCESSION NUMBER: 1998:88936 USPATFULL  
TITLE: Hormone-nuclease compounds and method for regulating hormone related diseases  
INVENTOR(S): Nett, Torrance M., Ft. Collins, CO, United States  
Glode, Leonard Michael, Aurora, CO, United States  
Karpeisky, Marat, Boulder, CO, United States  
PATENT ASSIGNEE(S): Colorado State University Research Foundation, Ft.  
Collins, CO, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5786457		19980728
APPLICATION INFO.:	US 1995-481128		19950607 (8)
RELATED APPLN. INFO.:			Continuation-in-part of Ser. No. US 1992-837639, filed on 14 Feb 1992, now patented, Pat. No. US 5378688, issued on 3 Jan 1995 which is a continuation-in-part of Ser. No. US 1989-314653, filed on 23 Feb 1989, now abandoned, said Ser. No. US 481128 which is a continuation-in-part of Ser. No. US 1993-88434, filed on 7 Jul 1993 Ser. No. Ser. No. US 1993-94250, filed on 20 Jul 1993, now patented, Pat. No. US 5492893 And Ser. No. US 1993-94625, filed on 20 Jul 1993, now patented, Pat. No. US 5488036

DOCUMENT TYPE: Utility  
FILE SEGMENT: Granted  
PRIMARY EXAMINER: Davenport, Avis M.  
LEGAL REPRESENTATIVE: Sheridan Ross, P.C.  
NUMBER OF CLAIMS: 9  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 8 Drawing Page(s)  
LINE COUNT: 2002

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI Hormone-nuclease compounds and method for regulating hormone related

diseases  
AB Certain toxic compounds (T) such as, for example, compounds based upon diphtheria **toxin**, ricin **toxin**, pseudomonas exotoxin,  $\alpha$ -amanitin, pokeweed antiviral protein (PAP), ribosome inhibiting proteins, especially the ribosome inhibiting proteins of barley, wheat, corn, rye, gelonin and abrin, as well as certain cytotoxic chemicals such as, for example, melphalan and daunomycin can be conjugated to certain analogs of gonadotropin-releasing hormone to form a class of compounds which, when injected into an animal, destroy the **gonadotrophs** of the animal's anterior pituitary gland. Hence such compounds may be used to **sterilize** such animals and/or to treat certain sex hormone related diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 6 OF 12 USPATFULL on STN

ACCESSION NUMBER: 1998:4563 USPATFULL  
TITLE: Method for treating cancer  
INVENTOR(S): Nett, Torrance M., Ft. Collins, CO, United States  
Glode, Leonard Michael, Aurora, CO, United States  
PATENT ASSIGNEE(S): Colorado State University Research Foundation, Fort Collins, CO, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5707964		19980113
APPLICATION INFO.:	US 1996-591917		19960126 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1993-88434, filed on 7 Jul 1993, now patented, Pat. No. US 5631229 which is a division of Ser. No. US 1992-837639, filed on 14 Feb 1992, now patented, Pat. No. US 5378688 which is a continuation-in-part of Ser. No. US 1989-314653, filed on 23 Feb 1989, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Davenport, Avis M.		
NUMBER OF CLAIMS:	2		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	8 Drawing Figure(s); 8 Drawing Page(s)		
LINE COUNT:	1345		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI Method for treating cancer

AB Certain toxic compounds (T) such as, for example, compounds based upon diphtheria **toxin**, ricin **toxin**, pseudomonas exotoxin,  $\alpha$ -amanitin, pokeweed antiviral protein (PAP), ribosome inhibiting proteins, especially the ribosome inhibiting proteins of barley, wheat, corn, rye, gelonin and abrin, as well as certain cytotoxic chemicals such as, for example, melphalan and daunomycin can be conjugated to certain analogs of gonadotropin-releasing hormone to form a class of compounds which, when injected into an animal, destroy the **gonadotrophs** of the animal's anterior pituitary gland. Hence such compounds may be used to **sterilize** such animals and/or to treat certain sex hormone related diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 7 OF 12 USPATFULL on STN

ACCESSION NUMBER: 97:42855 USPATFULL  
TITLE: Method for inactivating **gonadotrophs**  
INVENTOR(S): Nett, Torrance M., Ft. Collins, CO, United States  
Glode, Leonard M., Aurora, CO, United States  
PATENT ASSIGNEE(S): Colorado State University Research Foundation, Fort Collins, CO, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5631229		19970520
APPLICATION INFO.:	US 1993-88434		19930707 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1992-837639, filed on 14 Feb 1992, now patented, Pat. No. US 5378688 which is a continuation-in-part of Ser. No. US 1989-314653, filed on 23 Feb 1989, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Davenport, Avis M.		
LEGAL REPRESENTATIVE:	Sheridan Ross & McIntosh		
NUMBER OF CLAIMS:	27		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	8 Drawing Figure(s); 8 Drawing Page(s)		
LINE COUNT:	1459		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI Method for inactivating **gonadotrophs**  
 AB Certain toxic compounds (T) such as, for example, compounds based upon diphtheria **toxin**, ricin **toxin**, pseudomonas exotoxin,  $\alpha$ -amanitin, pokeweed antiviral protein (PAP), ribosome inhibiting proteins, especially the ribosome inhibiting proteins of barley, wheat, corn, rye, gelonin and abrin, as well as certain cytotoxic chemicals such as, for example, melphalan and daunomycin can be conjugated to certain analogs of gonadotropin-releasing hormone to form a class of compounds which, when injected into an animal, destroy the **gonadotrophs** of the animal's anterior pituitary gland. Hence such compounds may be used to **sterilize** such animals and/or to treat certain sex hormone related diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 8 OF 12 USPATFULL on STN  
 ACCESSION NUMBER: 96:14794 USPATFULL  
 TITLE: Hormone-**toxin conjugate** compounds  
 INVENTOR(S): Nett, Torrance M., Ft. Collins, CO, United States  
 Glode, Leonard M., Aurora, CO, United States  
 PATENT ASSIGNEE(S): Colorado State University Research Foundation, Fort Collins, CO, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5492893		19960220
APPLICATION INFO.:	US 1993-94250		19930720 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1992-837639, filed on 14 Feb 1992, now patented, Pat. No. US 5378688 which is a continuation-in-part of Ser. No. US 1989-314653, filed on 23 Feb 1989, now abandoned		

DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Warden, Jill		
ASSISTANT EXAMINER:	Huff, Sheela J.		
LEGAL REPRESENTATIVE:	Sheridan Ross & McIntosh		
NUMBER OF CLAIMS:	17		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	8 Drawing Figure(s); 8 Drawing Page(s)		
LINE COUNT:	1435		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI Hormone-**toxin conjugate** compounds  
 AB Certain toxic compounds (T) such as, for example, compounds based upon diphtheria **toxin**, ricin **toxin**, pseudomonas exotoxin,  $\alpha$ -amanitin, pokeweed antiviral protein (PAP), ribosome inhibiting

proteins, especially the ribosome inhibiting proteins of barley, wheat, corn, rye, gelonin and abrin, as well as certain cytotoxic chemicals such as, for example, melphalan and daunomycin can be conjugated to certain analogs of gonadotropin-releasing hormone to form a class of compounds which, when injected into an animal, destroy the **gonadotrophs** of the animal's anterior pituitary gland. Hence such compounds may be used to **sterilize** such animals and/or to treat certain sex hormone related diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 9 OF 12 USPATFULL on STN

ACCESSION NUMBER: 96:9411 USPATFULL

TITLE: Method for sterilizing animals using hormone-  
**toxin conjugate** compounds

INVENTOR(S): Nett, Torrance M., Ft. Collins, CO, United States  
Glode, Leonard M., Aurora, CO, United States

PATENT ASSIGNEE(S): Colorado State University Research Foundation, Fort  
Collins, CO, United States (U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 5488036 19960130

APPLICATION INFO.: US 1993-94625 19930720 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1992-837639, filed on 14 Feb 1992, now patented, Pat. No. US 5378688 which is a continuation-in-part of Ser. No. US 1989-314653, filed on 23 Feb 1989, now abandoned

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted

PRIMARY EXAMINER: Warden, Jill

ASSISTANT EXAMINER: Huff, Sheila J.

LEGAL REPRESENTATIVE: Sheridan Ross & McIntosh

NUMBER OF CLAIMS: 18

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 8 Drawing Figure(s); 8 Drawing Page(s)

LINE COUNT: 1447

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI Method for sterilizing animals using hormone-**toxin conjugate** compounds

AB Certain toxic compounds (T) such as, for example, compounds based upon diphtheria **toxin**, ricin **toxin**, pseudomonas exotoxin,  $\alpha$ -amanitin, pokeweed antiviral protein (PAP), ribosome inhibiting proteins, especially the ribosome inhibiting proteins of barley, wheat, corn, rye, gelonin and abrin, as well as certain cytotoxic chemicals such as, for example, melphalan and daunomycin can be conjugated to certain analogs of gonadotropin-releasing hormone to form a class of compounds which, when injected into an animal, destroy the **gonadotrophs** of the animal's anterior pituitary gland. Hence such compounds may be used to **sterilize** such animals and/or to treat certain sex hormone related diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 10 OF 12 USPATFULL on STN

ACCESSION NUMBER: 95:1591 USPATFULL

TITLE: GnRH analogs for destroying **gonadotrophs**

INVENTOR(S): Nett, Torrance M., Ft. Collins, CO, United States  
Glode, Leonard M., Aurora, CO, United States

PATENT ASSIGNEE(S): Colorado State University Research Foundation, Ft.  
Collins, CO, United States (U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 5378688 19950103  
 APPLICATION INFO.: US 1992-837639 19920214 (7)  
 RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1989-314653, filed  
 on 23 Feb 1989, now abandoned  
 DOCUMENT TYPE: Utility  
 FILE SEGMENT: Granted  
 PRIMARY EXAMINER: Hill, Jr., Robert J.  
 ASSISTANT EXAMINER: Davenport, A. M.  
 LEGAL REPRESENTATIVE: Sheridan Ross & McIntosh  
 NUMBER OF CLAIMS: 3  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 8 Drawing Figure(s); 8 Drawing Page(s)  
 LINE COUNT: 1354

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI GnRH analogs for destroying **gonadotrophs**  
 AB Certain toxic compounds (T) such as, for example, compounds based upon diphtheria **toxin**, ricin **toxin**, pseudomonas exotoxin,  $\alpha$ -amanitin, pokeweed antiviral protein (PAP), ribosome inhibiting proteins, especially the ribosome inhibiting proteins of barley, wheat, corn, rye, gelonin and abrin, as well as certain cytotoxic chemicals such as, for example, melphalan and daunomycin can be conjugated to certain analogs of gonadotropin-releasing hormone to form a class of compounds which, when injected into an animal, destroy the **gonadotrophs** of the animal's anterior pituitary gland. Hence such compounds may be used to **sterilize** such animals and/or to treat certain sex hormone related diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 1991:136750 CAPLUS  
 DOCUMENT NUMBER: 114:136750  
 TITLE: Congjugates of gonadotropin-releasing hormone analogs for destroying **gonadotrophs**  
 INVENTOR(S): Nett, Torrance M.; Glode, L. Michael  
 PATENT ASSIGNEE(S): Colorado State University Research Foundation, USA  
 SOURCE: PCT Int. Appl., 49 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 6  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9009799	A1	19900907	WO 1990-US1038	19900220
W: AU, CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE				
AU 9051860	A1	19900926	AU 1990-51860	19900220
ZA 9001391	A	19911030	ZA 1990-1391	19900223
PRIORITY APPLN. INFO.:			US 1989-314653	A 19890223
			WO 1990-US1038	A 19900220

OTHER SOURCE(S): MARPAT 114:136750

TI Congjugates of gonadotropin-releasing hormone analogs for destroying **gonadotrophs**  
 AB Certain toxic compds. such as, diphtheria **toxin**, ricin **toxin**, Pseudomonas exotoxin,  $\alpha$ -amanitin, pokeweed antiviral protein, ribosome-inhibiting proteins of cereals, gelonin and abrin, as well as certain cytotoxic chems. such as, melphalan and daunorubicin, can be conjugated to analogs of gonadotropin-releasing hormone GnRH to form compds. which, when injected into an animal, destroy the **gonadotrophs** of the anterior pituitary gland. Hence, such compds.

may be used to **sterilize** animals and/or to treat certain sex hormone-related diseases, such as prostate and breast cancer. [D-Lys6, des-Gly10]-GnRH-ethylamide, synthesized by the solid phase method, was conjugated with pokeweed antiviral protein, using N-succinidinyl 3-(2-pyridyldithio) propionate. Four injections of the **conjugate**, at 3 day intervals, totally sterilized female rats, and partially male rats.

L10 ANSWER 12 OF 12 TOXCENTER COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 1991:125404 TOXCENTER  
COPYRIGHT: Copyright 2005 ACS  
DOCUMENT NUMBER: CA11415136750Z  
TITLE: Congugates of gonadotropin-releasing hormone analogs for destroying **gonadotrophs**  
AUTHOR(S): Nett, Torrance M.; Glode, L. Michael  
CORPORATE SOURCE: ASSIGNEE: Colorado State University Research Foundation  
PATENT INFORMATION: WO 909799 A1 7 Sep 1990  
SOURCE: (1990) PCT Int. Appl., 49 pp.  
CODEN: PIXXD2.  
COUNTRY: UNITED STATES  
DOCUMENT TYPE: Patent  
FILE SEGMENT: CAPLUS  
OTHER SOURCE: CAPLUS 1991:136750  
LANGUAGE: English  
ENTRY DATE: Entered STN: 20011116  
Last Updated on STN: 20021015  
TI Congugates of gonadotropin-releasing hormone analogs for destroying **gonadotrophs**  
AB Certain toxic compds. such as, diphtheria **toxin**, ricin **toxin**, Pseudomonas exotoxin,  $\alpha$ -amanitin, pokeweed antiviral protein, ribosome-inhibiting proteins of cereals, gelonin and abrin, as well as certain cytotoxic chems. such as, melphalan and daunorubicin, can be conjugated to analogs of gonadotropin-releasing hormone GnRH to form compds. which, when injected into an animal, destroy the **gonadotrophs** of the anterior pituitary gland. Hence, such compds. may be used to **sterilize** animals and/or to treat certain sex hormone-related diseases, such as prostate and breast cancer. [D-Lys6, des-Gly10]-GnRH-ethylamide, synthesized by the solid phase method, was conjugated with pokeweed antiviral protein, using N-succinidinyl 3-(2-pyridyldithio) propionate. Four injections of the **conjugate**, at 3 day intervals, totally sterilized female rats, and partially male rats.

=> d his

(FILE 'HOME' ENTERED AT 15:10:16 ON 16 FEB 2005)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, ...' ENTERED AT 15:10:41 ON 16 FEB 2005  
SEA GONADOTROPH AND CONJUGATE

-----  
1 FILE BIOBUSINESS  
4 FILE BIOENG  
7 FILE BIOSIS  
1 FILE BIOTECHABS  
1 FILE BIOTECHDS  
1 FILE BIOTECHNO  
1 FILE CANCERLIT  
22 FILE CAPLUS  
21 FILE DGENE

1 FILE DRUGU  
4 FILE EMBASE  
3 FILE ESBIOBASE  
2 FILE FEDRIP  
9 FILE IFIPAT  
5 FILE LIFESCI  
6 FILE MEDLINE  
2 FILE PASCAL  
3 FILE SCISEARCH  
16 FILE TOXCENTER  
43 FILE USPATFULL  
5 FILE USPAT2  
1 FILE VETU  
8 FILE WPIDS  
8 FILE WPINDEX

L1 QUE GONADOTROPH AND CONJUGATE

-----

FILE 'MEDLINE, USPATFULL, CAPLUS, DGENE, TOXCENTER, IFIPAT, WPIDS, BIOSIS, EMBASE' ENTERED AT 15:12:23 ON 16 FEB 2005

L2 244 S GONADOTROPH AND TOXIN  
L3 136 S CONJUGATE AND GONADOTROPH  
L4 79 S L3 AND TOXIN  
L5 47 DUP REM L4 (32 DUPLICATES REMOVED)  
L6 14 S L5 AND STERILIZE  
L7 834 S NETT, T?/AU  
L8 333 DUP REM L7 (501 DUPLICATES REMOVED)  
L9 2 S L6 NOT L8  
L10 12 S L6 NOT L9

=> s 15 AND (methotrexate OR nitrogen(w)mustard OR doxorubicin OR daunomycin OR ribosome(w)inhibiting(w)protein)

2 FILES SEARCHED...  
4 FILES SEARCHED...

L11 24 L5 AND (METHOTREXATE OR NITROGEN(W) MUSTARD OR DOXORUBICIN OR DAUNOMYCIN OR RIBOSOME(W) INHIBITING(W) PROTEIN)

=> dup rem l11

DUPLICATE IS NOT AVAILABLE IN 'DGENE'.

ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE

PROCESSING COMPLETED FOR L11

L12 24 DUP REM L11 (0 DUPLICATES REMOVED)

=> d his

(FILE 'HOME' ENTERED AT 15:10:16 ON 16 FEB 2005)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, ...' ENTERED AT 15:10:41 ON 16 FEB 2005  
SEA GONADOTROPH AND CONJUGATE

-----  
1 FILE BIOBUSINESS  
4 FILE BIOENG  
7 FILE BIOSIS  
1 FILE BIOTECHABS  
1 FILE BIOTECHDS  
1 FILE BIOTECHNO  
1 FILE CANCERLIT  
22 FILE CAPLUS  
21 FILE DGENE  
1 FILE DRUGU

4 FILE EMBASE  
3 FILE ESBIOBASE  
2 FILE FEDRIP  
9 FILE IFIPAT  
5 FILE LIFESCI  
6 FILE MEDLINE  
2 FILE PASCAL  
3 FILE SCISEARCH  
16 FILE TOXCENTER  
43 FILE USPATFULL  
5 FILE USPAT2  
1 FILE VETU  
8 FILE WPIDS  
8 FILE WPINDEX  
L1 QUE GONADOTROPH AND CONJUGATE

---

FILE 'MEDLINE, USPATFULL, CAPLUS, DGENE, TOXCENTER, IFIPAT, WPIDS, BIOSIS, EMBASE' ENTERED AT 15:12:23 ON 16 FEB 2005

L2 244 S GONADOTROPH AND TOXIN  
L3 136 S CONJUGATE AND GONADOTROPH  
L4 79 S L3 AND TOXIN  
L5 47 DUP REM L4 (32 DUPLICATES REMOVED)  
L6 14 S L5 AND STERILIZE  
L7 834 S NETT,T?/AU  
L8 333 DUP REM L7 (501 DUPLICATES REMOVED)  
L9 2 S L6 NOT L8  
L10 12 S L6 NOT L9  
L11 24 S L5 AND (METHOTREXATE OR NITROGEN(W) MUSTARD OR DOXORUBICIN OR  
L12 24 DUP REM L11 (0 DUPLICATES REMOVED)

=> s l12 NOT L8

L13 9 L12 NOT L8

=> d his

(FILE 'HOME' ENTERED AT 15:10:16 ON 16 FEB 2005)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, ...' ENTERED AT 15:10:41 ON 16 FEB 2005  
SEA GONADOTROPH AND CONJUGATE

---

1 FILE BIOBUSINESS  
4 FILE BIOENG  
7 FILE BIOSIS  
1 FILE BIOTECHABS  
1 FILE BIOTECHDS  
1 FILE BIOTECHNO  
1 FILE CANCERLIT  
22 FILE CAPLUS  
21 FILE DGENE  
1 FILE DRUGU  
4 FILE EMBASE  
3 FILE ESBIOBASE  
2 FILE FEDRIP  
9 FILE IFIPAT  
5 FILE LIFESCI  
6 FILE MEDLINE  
2 FILE PASCAL  
3 FILE SCISEARCH  
16 FILE TOXCENTER

43 FILE USPATFULL  
5 FILE USPAT2  
1 FILE VETU  
8 FILE WPIDS  
8 FILE WPINDEX  
L1 QUE GONADOTROPH AND CONJUGATE  
-----

FILE 'MEDLINE, USPATFULL, CAPLUS, DGENE, TOXCENTER, IFIPAT, WPIDS, BIOSIS, EMBASE' ENTERED AT 15:12:23 ON 16 FEB 2005  
L2 244 S GONADOTROPH AND TOXIN  
L3 136 S CONJUGATE AND GONADOTROPH  
L4 79 S L3 AND TOXIN  
L5 47 DUP REM L4 (32 DUPLICATES REMOVED)  
L6 14 S L5 AND STERILIZE  
L7 834 S NETT,T?/AU  
L8 333 DUP REM L7 (501 DUPLICATES REMOVED)  
L9 2 S L6 NOT L8  
L10 12 S L6 NOT L9  
L11 24 S L5 AND (METHOTREXATE OR NITROGEN (W) MUSTARD OR DOXORUBICIN OR  
L12 24 DUP REM L11 (0 DUPLICATES REMOVED)  
L13 9 S L12 NOT L8

=> d 113 ibib ti abs 1-9

L13 ANSWER 1 OF 9 USPATFULL on STN  
ACCESSION NUMBER: 2004:337325 USPATFULL  
TITLE: Soluble hyaluronidase glycoprotein (sHASEGP), process  
for preparing the same, uses and pharmaceutical  
compositions comprising thereof  
INVENTOR(S): Bookbinder, Louis H., San Diego, CA, UNITED STATES  
Kundu, Anirban, San Diego, CA, UNITED STATES  
Frost, Gregory I., Del Mar, CA, UNITED STATES  
PATENT ASSIGNEE(S): Deliatroph Pharmaceuticals, Inc., San Diego, CA (U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004268425	A1	20041230
APPLICATION INFO.:	US 2004-795095	A1	20040305 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-452360P	20030305 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GRAY CARY WARE & FREIDENRICH LLP, 4365 EXECUTIVE DRIVE, SUITE 1100, SAN DIEGO, CA, 92121-2133	
NUMBER OF CLAIMS:	161	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	7714	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the  
same, uses and pharmaceutical compositions comprising thereof  
AB The invention relates to the discovery of novel soluble neutral active  
Hyaluronidase Glycoproteins (sHASEGP's), methods of manufacture, and  
their use to facilitate administration of other molecules or to  
alleviate glycosaminoglycan associated pathologies. Minimally active  
polypeptide domains of the soluble, neutral active sHASEGP domains are  
described that include asparagine-linked sugar moieties required for a  
functional neutral active hyaluronidase domain. Included are modified  
amino-terminal leader peptides that enhance secretion of sHASEGP. The

invention further comprises sialated and pegylated forms of a recombinant SHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant SHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 2 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2004:25125 USPATFULL

TITLE: Ligand/lytic peptide compositions and methods of use

INVENTOR(S): Enright, Frederick M., Baton Rouge, LA, UNITED STATES

Jaynes, Jesse M., Raleigh, NC, UNITED STATES

Hansel, William, Baton Rouge, LA, UNITED STATES

Koonce, Kenneth L., Baton Rouge, LA, UNITED STATES

McCann, Samuel M., Baton Rouge, LA, UNITED STATES

Yu, Wen H., Baton Rouge, LA, UNITED STATES

Melrose, Patricia A., Baton Rouge, LA, UNITED STATES

Foil, Lane D., Baton Rouge, LA, UNITED STATES

Elzer, Philip H., Baton Rouge, LA, UNITED STATES

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 2004018967 A1 20040129

APPLICATION INFO.: US 2003-617561 A1 20030711 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1999-381879, filed on 24 Sep 1999, GRANTED, Pat. No. US 6635740 A 371 of International Ser. No. WO 1998-US6114, filed on 27 Mar 1998, PENDING

NUMBER	DATE
--------	------

PRIORITY INFORMATION: US 1997-41009P 19970327 (60)

US 1997-92112P 19970604 (60)

US 1997-57456P 19970903 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: PATENT DEPARTMENT, TAYLOR, PORTER, BROOKS & PHILLIPS, L.L.P., P.O. BOX 2471, BATON ROUGE, LA, 70821-2471

NUMBER OF CLAIMS: 128

EXEMPLARY CLAIM: 1

LINE COUNT: 2095

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI Ligand/lytic peptide compositions and methods of use

AB Amphipathic lytic peptides are ideally suited to use in a ligand/cytotoxin combination to specifically inhibit cells that are driven by or are dependent upon a specific ligand interaction; for example, to induce sterility or long-term contraception, or to attack tumor cells, or to selectively lyse virally-infected cells, or to attack lymphocytes responsible for autoimmune diseases. The peptides act directly on cell membranes, and need not be internalized. Administering a combination of gonadotropin-releasing hormone (GnRH) (or a GnRH agonist) and a membrane-active lytic peptide produces long-term contraception or sterilization in animals *in vivo*. Administering *in vivo* a combination of a ligand and a membrane-active lytic peptide kills cells with a receptor for the ligand. The compounds are relatively small, and are not antigenic. Lysis of gonadotropes has been observed to be very rapid (on the order of ten minutes.) Lysis of tumor cells is rapid. The two components--the ligand and the lytic peptide--may optionally be administered as a fusion peptide, or they may be administered separately, with the ligand administered slightly before the lytic peptide, to activate cells with receptors for the ligand, and

thereby make those cells susceptible to lysis by the lytic peptide. The compounds may be used in gene therapy to treat malignant or non-malignant tumors, and other diseases caused by clones or populations of "normal" host cells bearing specific receptors (such as lymphocytes), because genes encoding a lytic peptide or encoding a lytic peptide/peptide hormone fusion may readily be inserted into hematopoietic stem cells or myeloid precursor cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 3 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2004:14940 USPATFULL

TITLE: Compositions and methods for contraception in or sterilization of mammals

INVENTOR(S): Enright, Frederick M., Baton Rouge, LA, United States  
Jaynes, Jesse M., Baton Rouge, LA, United States  
Hansel, William, Baton Rouge, LA, United States  
Melrose, Patricia A., Baton Rouge, LA, United States  
Elzer, Philip H., Baton Rouge, LA, United States

PATENT ASSIGNEE(S): Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, Baton Rouge, LA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6680058	B1	20040120
	WO 9911282		19990311
APPLICATION INFO.:	US 2000-486143		20000222 (9)
	WO 1998-US18117		19980901

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-57456P	19970903 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: GRANTED

PRIMARY EXAMINER: Kunz, Gary

ASSISTANT EXAMINER: Hamud, Fozia

LEGAL REPRESENTATIVE: Runnels, John H.

NUMBER OF CLAIMS: 39

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)

LINE COUNT: 1259

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI Compositions and methods for contraception in or sterilization of mammals

AB Amphipathic lytic peptides are ideally suited to use in a ligand/cytotoxin combination to induce sterility or long-term contraception in mammals. The peptides act directly on cell membranes, and need not be internalized. Administering a combination of gonadotropin-releasing hormone (GnRH) (or a GnRH agonist) and a membrane-active lytic peptide produces long-term contraception or sterilization in mammals in vivo. The compounds are relatively small, and are not antigenic. Lysis of gonadotropes has been observed to be very rapid (on the order of ten minutes.) The two components--the ligand and the lytic peptide--may optionally be administered as a fusion peptide, or they may be administered separately, with the ligand administered slightly before the lytic peptide, to activate cells with receptors for the ligand, and thereby make those cells susceptible to lysis by the lytic peptide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 4 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2003:279230 USPATFULL  
 TITLE: Ligand/lytic peptide compositions and methods of use  
 INVENTOR(S): Enright, Frederick M., Baton Rouge, LA, United States  
 Jaynes, Jesse M., Baton Rouge, LA, United States  
 Hansel, William, Baton Rouge, LA, United States  
 Koonce, Kenneth L., Baton Rouge, LA, United States  
 McCann, Samuel M., Baton Rouge, LA, United States  
 Yu, Wen H., Baton Rouge, LA, United States  
 Melrose, Patricia A., Baton Rouge, LA, United States  
 Foil, Lane D., Baton Rouge, LA, United States  
 Elzer, Philip H., Baton Rouge, LA, United States  
 PATENT ASSIGNEE(S): Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, Baton Rouge, LA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6635740	B1	20031021
	WO 9842365		19981001
APPLICATION INFO.:	US 1999-381879		19990924 (9)
	WO 1998-US6114		19980327

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-57456P	19970903 (60)
	US 1997-92112P	19970604 (60)
	US 1997-41009P	19970327 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Low, Christopher S. F.	
ASSISTANT EXAMINER:	Lukton, David	
LEGAL REPRESENTATIVE:	Runnels, John H.	
NUMBER OF CLAIMS:	109	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	2428	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI Ligand/lytic peptide compositions and methods of use  
 AB Amphipathic lytic peptides are ideally suited to use in a ligand/cytotoxin combination to specifically inhibit cells that are driven by or are dependent upon a specific ligand interaction; for example, to induce sterility or long-term contraception, or to attack tumor cells, or to selectively lyse virally-infected cells, or to attack lymphocytes responsible for autoimmune diseases. The peptides act directly on cell membranes, and need not be internalized. Administering a combination of gonadotropin-releasing hormone (GnRH) (or a GnRH agonist) and a membrane-active lytic peptide produces long-term contraception or sterilization in animals *in vivo*. Administering *in vivo* a combination of a ligand and a membrane-active lytic peptide kills cells with a receptor for the ligand. The compounds are relatively small, and are not antigenic. Lysis of gonadotropes has been observed to be very rapid (on the order of ten minutes.) Lysis of tumor cells is rapid. The two components--the ligand and the lytic peptide--may optionally be administered as a fusion peptide, or they may be administered separately, with the ligand administered slightly before the lytic peptide, to activate cells with receptors for the ligand, and thereby make those cells susceptible to lysis by the lytic peptide. The compounds may be used in gene therapy to treat malignant or non-malignant tumors, and other diseases caused by clones or populations of "normal" host cells bearing specific receptors (such as lymphocytes), because genes encoding a lytic peptide or encoding a lytic peptide/peptide hormone fusion may readily be inserted into hematopoietic stem cells or myeloid precursor cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 5 OF 9 USPATFULL on STN  
ACCESSION NUMBER: 2003:232514 USPATFULL  
TITLE: Follistatin-3  
INVENTOR(S): Duan, D. Roxanne, Bethesda, MD, UNITED STATES  
Ruben, Steven M., Brookeville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003162715	A1	20030828
APPLICATION INFO.:	US 2003-372874	A1	20030226 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2000-617804, filed on 14 Jul 2000, GRANTED, Pat. No. US 6537966 Division of Ser. No. US 1998-141027, filed on 27 Aug 1998, GRANTED, Pat. No. US 6372454		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-144088P	19990716 (60)
	US 1997-56248P	19970829 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Page(s)	
LINE COUNT:	8961	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI Follistatin-3  
AB The present invention relates to a novel follistatin-3 protein which is a member of the family of inhibin-related proteins. In particular, isolated nucleic acid molecules are provided encoding the human follistatin-3 protein. Follistatin-3 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of follistatin-3 activity. Also provided are diagnostic methods for detecting reproductive system-related disorders and disorders of the regulation of cell growth and differentiation and therapeutic methods for treating reproductive system-related disorders and disorders of the regulation of cell growth and differentiation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 6 OF 9 USPATFULL on STN  
ACCESSION NUMBER: 2003:81717 USPATFULL  
TITLE: Follistatin-3  
INVENTOR(S): Duan, D. Roxanne, Bethesda, MD, United States  
Ruben, Steven M., Olney, MD, United States  
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6537966	B1	20030325
APPLICATION INFO.:	US 2000-617804		20000714 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-141027, filed on 27 Aug 1998 Continuation-in-part of Ser. No. WO 1998-US17710, filed on 27 Aug 1998		

NUMBER DATE

PRIORITY INFORMATION: US 1999-144088P 19990716 (60)  
 US 1997-56248P 19970829 (60)  
 DOCUMENT TYPE: Utility  
 FILE SEGMENT: GRANTED  
 PRIMARY EXAMINER: Mertz, Prema  
 LEGAL REPRESENTATIVE: Human Genome Sciences, Inc.  
 NUMBER OF CLAIMS: 67  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 5 Drawing Figure(s); 5 Drawing Page(s)  
 LINE COUNT: 8929

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI Follistatin-3  
 AB The present invention relates to a novel follistatin-3 protein which is a member of the family of inhibin-related proteins. In particular, isolated nucleic acid molecules are provided encoding the human follistatin-3 protein. Follistatin-3 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of follistatin-3 activity. Also provided are diagnostic methods for detecting reproductive system-related disorders and disorders of the regulation of cell growth and differentiation and therapeutic methods for treating reproductive system-related disorders and disorders of the regulation of cell growth and differentiation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 7 OF 9 USPATFULL on STN  
 ACCESSION NUMBER: 2001:18620 USPATFULL  
 TITLE: Targeted cytotoxic anthracycline analogs  
 INVENTOR(S): Schally, Andrew V., Metairie, LA, United States  
 Nagy, Attila A., Metairie, LA, United States  
 Cai, Ren-Zhi, Metairie, LA, United States  
 PATENT ASSIGNEE(S): The Administrators of the Tulane Educational Fund, New Orleans, LA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6184374	B1	20010206
APPLICATION INFO.:	US 1998-116125		19980715 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-562652, filed on 22 Nov 1995, now patented, Pat. No. US 5843903		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Woodward, Michael P.		
ASSISTANT EXAMINER:	Gupta, Anish		
LEGAL REPRESENTATIVE:	Behr, Esq., Omri M.		
NUMBER OF CLAIMS:	5		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	4 Drawing Figure(s); 4 Drawing Page(s)		
LINE COUNT:	1192		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI Targeted cytotoxic anthracycline analogs  
 AB This invention is in the field of the chemistry of targeting anticancer anthracycline derivatives. More particularly, it concerns doxorubicin (DOX) or its daunosamine modified derivatives (DM-DOX) linked covalently to analogs of peptide hormones such as LH-RH, bombesin and somatostatin. These covalent conjugates are targeted to various tumors bearing receptors for the peptide hormone analogs. The compounds of this invention are represented by General Formula Q.sup.14 --O--R--P wherein Q has the general formula ##STR1##  
 wherein: Q.sup.14 signifies a Q moiety with a side chain at the 14

position, R-- is H or --C(O)--(CH<sub>2</sub>.sub.2).sub.n --C(O)-- and n=0-7, R' is NH<sub>2</sub>.sub.2 or an aromatic, saturated or partially saturated 5 or 6 membered heterocyclic compounds having at least one ring nitrogen and optionally having a butadiene moiety bonded to adjacent carbon atoms of said ring to form a bicyclic system; P is H or a peptide moiety, suitably an LHRH, somatostatin or bombesin analogs. Nevertheless where R' is NH<sub>2</sub>.sub.2 then R and P are other than H. When R and P are H, then R' is other than NH<sub>2</sub>.sub.2. A novel synthetic reaction has been discovered in the course of this work to form partially saturated heterocyclic moieties from vicinal and disjunct i.e.,  $\alpha$ ,  $\beta$  or  $\alpha$ ,  $\gamma$  hydroxy primary amines.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 8 OF 9 USPATFULL on STN

ACCESSION NUMBER: 2000:146112 USPATFULL

TITLE: Methods of cancer diagnosis using a chimeric  
toxin

INVENTOR(S): Lorberboum-Galski, Haya, 723 Bar Kochva Street,  
Jerusalem 97875, Israel  
Yarkoni, Shai, 33 Lamed Hei Street, Kfar-Saba 44395,  
Israel  
Ben-Yehudah, Ahmi, Neve Ilan, D.N. Harei Yehuda 90852,  
Israel  
Marianovsky, Irina, 601/73 Neve Jacob, Jerusalem,  
Israel  
Nechushtan, Amotz, 214 Banim Street, Ramat Hsharon  
47223, Israel

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6140066		20001031
APPLICATION INFO.:	US 1998-46992		19980324 (9)
DOCUMENT TYPE:		Utility	
FILE SEGMENT:		Granted	
PRIMARY EXAMINER:	Huff, Sheela		
LEGAL REPRESENTATIVE:	Pennie & Edmonds		
NUMBER OF CLAIMS:	37		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	6 Drawing Figure(s); 7 Drawing Page(s)		
LINE COUNT:	1149		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

TI Methods of cancer diagnosis using a chimeric toxin

AB The present invention relates to methods for cancer diagnosis using a chimeric toxin. In particular, the invention relates to the use of a chimeric toxin composed of gonadotropin releasing hormone (GnRH) and Pseudomonas exotoxin A (PE) to detect a tumor-associated epitope expressed by human adenocarcinomas. Mutated GnRH-PE molecules that bind but do not kill tumor cells are exemplified.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 9 OF 9 USPATFULL on STN

ACCESSION NUMBER: 1998:150906 USPATFULL

TITLE: Targeted cytotoxic anthracycline analogs

INVENTOR(S): Schally, Andrew V., Metairie, LA, United States  
Nagy, Attila A., Metairie, LA, United States  
Cai, Ren-Zhi, Metairie, LA, United States

PATENT ASSIGNEE(S): The Administrators of the Tulane Educational Fund, New Orleans, LA, United States (U.S. corporation)

	NUMBER	KIND	DATE
--	--------	------	------

PATENT INFORMATION: US 5843903 19981201  
APPLICATION INFO.: US 1995-562652 19951127 (8)  
DOCUMENT TYPE: Utility  
FILE SEGMENT: Granted  
PRIMARY EXAMINER: Tsang, Cecilia J.  
ASSISTANT EXAMINER: Gupa, Anish  
LEGAL REPRESENTATIVE: Behr, Esq., Omri M.  
NUMBER OF CLAIMS: 27  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 4 Drawing Page(s)  
LINE COUNT: 1321  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
TI Targeted cytotoxic anthracycline analogs  
AB This invention is in the field of the chemistry of targeting anticancer anthracycline derivatives. More particularly, it concerns doxorubicin (DOX) or its daunosamine modified derivatives (DM-DOX) linked covalently to analogs of peptide hormones such as LH-RH, bombesin and somatostatin. These covalent conjugates are targeted to various tumors bearing receptors for the peptide hormone analogs. The compounds of this invention are represented by General Formula Q.sup.14 --O--R--P wherein Q has the general formula ##STR1## wherein: Q.sup.14 signifies a Q moiety with a side chain at the 14 position, R-- is H or --C(O)--(CH.sub.2).sub.n --C(O)-- and n=0-7, R' is NH.sub.2 or an aromatic, saturated or partially saturated 5 or 6 membered heterocyclic compounds having at least one ring nitrogen and optionally having a butadiene moiety bonded to adjacent carbon atoms of said ring to form a bicyclic system; P is H or a peptide moiety, suitably an LHRH, somatostatin or bombesin analogs. Nevertheless where R' is NH.sub.2 then R and P are other than H. When R and P are H, then R' is other than NH.sub.2. A novel synthetic reaction has been discovered in the course of this work to form partially saturated heterocyclic moieties from vicinal and disjunct i.e., α, β, or α, γ hydroxy primary amines.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> DIS HIST

(FILE 'HOME' ENTERED AT 15:10:16 ON 16 FEB 2005)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, ...' ENTERED AT 15:10:41 ON 16 FEB 2005  
SEA GONADOTROPH AND CONJUGATE

-----  
1 FILE BIOBUSINESS  
4 FILE BIOENG  
7 FILE BIOSIS  
1 FILE BIOTECHABS  
1 FILE BIOTECHDS  
1 FILE BIOTECHNO  
1 FILE CANCERLIT  
22 FILE CAPLUS  
21 FILE DGENE  
1 FILE DRUGU  
4 FILE EMBASE  
3 FILE ESBIOBASE  
2 FILE FEDRIP  
9 FILE IFIPAT  
5 FILE LIFESCI  
6 FILE MEDLINE

2 FILE PASCAL  
3 FILE SCISEARCH  
16 FILE TOXCENTER  
43 FILE USPATFULL  
5 FILE USPAT2  
1 FILE VETU  
8 FILE WPIDS  
8 FILE WPINDEX  
L1 QUE GONADOTROPH AND CONJUGATE  
-----

FILE 'MEDLINE, USPATFULL, CAPLUS, DGENE, TOXCENTER, IFIPAT, WPIDS, BIOSIS, EMBASE' ENTERED AT 15:12:23 ON 16 FEB 2005

L2 244 S GONADOTROPH AND TOXIN  
L3 136 S CONJUGATE AND GONADOTROPH  
L4 79 S L3 AND TOXIN  
L5 47 DUP REM L4 (32 DUPLICATES REMOVED)  
L6 14 S L5 AND STERILIZE  
L7 834 S NETT,T?/AU  
L8 333 DUP REM L7 (501 DUPLICATES REMOVED)  
L9 2 S L6 NOT L8  
L10 12 S L6 NOT L9  
L11 24 S L5 AND (METHOTREXATE OR NITROGEN(W) MUSTARD OR DOXORUBICIN OR  
L12 24 DUP REM L11 (0 DUPLICATES REMOVED)  
L13 9 S L12 NOT L8

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	91.14	93.12
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.73	-0.73

STN INTERNATIONAL LOGOFF AT 15:22:32 ON 16 FEB 2005